The problem
People wanting weight-loss medication face slow, costly GP access; AIOS sells branded GLP-1s online at the lowest cash price
What they do
Online GLP-1 weight-loss clinics and pharmacy (Bolt Pharmacy UK, Fella Health) run on its own AI clinical stack
Traction ~$400M ARR (company-stated, Sep 2026), up from ~$10M a year earlier; Sacra est. $420-450M; profitable, ~20% gross margin
Hiring trend
- Open roles
- 18
- Ops roles
- 1
- Headcount
- ~100-125
Layoff Jun 2025 (~170 → ~95); rebuilt to ~125 on LinkedIn (+32% YoY); 18 open roles, all posted May-Oct 2026
Hiring in
- Berlin
- Blackburn
- European timezones
- Remote (Europe)
- Remote (UK)
Latest news
Oct 2026
UK pharmacy regulator GPhC found Bolt Pharmacy failed two standards; improvement plan due Oct 9 ↗Glassdoor
3.8 ★ 29 reviews ↗Funding
- Last round
- none (bootstrapped; ~$75K-$225K 2021 seed)
- Stage
- Bootstrapped (tiny 2021 seed only)
Led by BrandProject (2021 seed); Y Combinator, Global Founders Capital, AngelList
- Hiring+1.518 open roles on the live job board (10–29 roles = +1.5)
- Funding recency0Bootstrapped (tiny 2021 seed only) · none (bootstrapped; ~$75K-$225K 2021 seed): no round date on file, so no recency points
- Traction0No growth signal counted: ~$400M ARR (company-stated, Sep 2026), up from ~$10M a year earlier; Sacra est. $420-450M; profitable, ~20% gross margin
- Red flags0Watch-outs noted below, none scored as a significant flag
- Total1.51.5 + 0 + 0 − 0 = 1.5 → Steady (1.5–3.49)
Distance (10K) is a separate read on how long the lead can last. It doesn't change the score.
Distance
10K · edge: cheaper at size
Explosive UK growth, but it resells branded Wegovy/Mounjaro at cost (~20% gross margin) in a crowded online-pharmacy market (Voy, Juniper, Numan, Hims via ZAVA), depends on Lilly/Novo pricing and paid social ads, and faces mounting UK regulatory pressure.
Sources: Sacra: AIOS ~20% gross margins vs 65-80% at Ro/Hims (2026) ↗ · Sacra: AIOS pivot to UK branded supply; Hims entered UK via ZAVA ↗ · Chemist+Druggist: GPhC action against Voy and Bolt (Oct 2026) ↗
Watch-outs
Jun 2025 layoff of ~75 of ~170 staff (~44%) after US compounded-GLP-1 revenue fell (Sacra: $82M → $54M annualized, Mar-Sep 2025). Eli Lilly (Apr 2025) and Novo Nordisk (Aug 2025) federal lawsuits over compounded GLP-1 marketing; Lilly's suit largely survived dismissal Mar 2026. UK regulators on Bolt Pharmacy: MHRA ad action (Mar 2026), two upheld ASA rulings incl. a fake 'independent' reviews page (Jul 2026), GPhC inspection 'standards not all met' (Jul 2026, published Oct 2026). Also: US Fella Health has paused new sign-ups (Oct 2026).
Sources: Richie Cartwright (CEO) on LinkedIn: letting go ~75, team ~170 to ~95 (Jun 2025) ↗ · Sacra: AIOS revenue fell $82M to $54M annualized in 2025 before UK pivot (Jul 2026) ↗ · MobiHealthNews: Eli Lilly sues four telehealth companies incl. Fella Health (Apr 2025) ↗ · Reuters: Novo Nordisk expands compounder lawsuits, names Fella Health (Aug 2025) ↗ · VitalLaw: Lilly mostly survives Aios motion to dismiss, N.D. Cal. (Mar 2026) ↗ · GOV.UK MHRA: Bolt Healthcare t/a Bolt Pharmacy and Fella Health amended weight-loss ads (Mar 2026) ↗ · ASA ruling on Bolt Pharmacy: 'UK Weight Loss Reviews' page, upheld (Jul 2026) ↗ · ASA ruling on Bolt Pharmacy: POM promotion, upheld (Jul 2026) ↗ · GPhC inspection: Bolt Pharmacy 'Standards not all met' (Jul 2026) ↗ · Chemist+Druggist: GPhC takes action against Voy and Bolt (Oct 2026) ↗ · Fella Health site: new sign-ups temporarily paused (Oct 2026) ↗
Open ops roles · 1
Last checked Oct 25, 2026